Thompson Davis & Co’s Rocket Pharmaceuticals RCKT Stock Holding History

Thompson Davis & Co’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,250	Closed	-$10K	–	1155
2017 Q1	$10K	Buy	+1,250	New	+$8.41K	0.01%	694

Other funds holding RCKT

RCP

Rho Capital Partners New York $20.4M AUM

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Thompson Davis & Co's RCKT Position: Q2 2017 in Review

Thompson Davis & Co sold out of Rocket Pharmaceuticals (RCKT) in Q2 2017, closing a stake of 1,250 shares — an estimated $10K sold.

Thompson Davis & Co first reported a position in RCKT in Q1 2017 and held it in 1 quarter. The position peaked at $10K in Q1 2017. 51 funds tracked by Wall St. Rank hold RCKT as of Q2 2017.

Thompson Davis & Co reported no remaining Rocket Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Thompson Davis & Co sold 1,250 Rocket Pharmaceuticals shares in Q2 2017, an estimated $10K.
Thompson Davis & Co first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Thompson Davis & Co's Rocket Pharmaceuticals position peaked at $10K in Q1 2017.
51 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.